BR112022004995A2 - Anticorpos biespecíficos contra ceacam5 e cd3 - Google Patents

Anticorpos biespecíficos contra ceacam5 e cd3

Info

Publication number
BR112022004995A2
BR112022004995A2 BR112022004995A BR112022004995A BR112022004995A2 BR 112022004995 A2 BR112022004995 A2 BR 112022004995A2 BR 112022004995 A BR112022004995 A BR 112022004995A BR 112022004995 A BR112022004995 A BR 112022004995A BR 112022004995 A2 BR112022004995 A2 BR 112022004995A2
Authority
BR
Brazil
Prior art keywords
bispecific antibodies
antibodies against
ceacam5
relates
antibodies
Prior art date
Application number
BR112022004995A
Other languages
English (en)
Inventor
Klaus Strein
Sara Majocchi
Original Assignee
Lamkap Bio Alpha AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lamkap Bio Alpha AG filed Critical Lamkap Bio Alpha AG
Publication of BR112022004995A2 publication Critical patent/BR112022004995A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

anticorpos biespecíficos contra ceacam5 e cd3. a presente invenção refere-se a anticorpos biespecíficos que se ligam ao antígeno carcinoembriogênico humano ceacam5 (cea) e cd3¿ humano. além disso, a presente invenção refere-se a polinucleotídeos que codificam tais anticorpos biespecíficos e vetores e células hospedeiras que compreendem tais polinucleotídeos. a invenção também se refere aos métodos para a seleção e a produção de tais anticorpos e aos métodos de uso de tais anticorpos no tratamento de doenças.
BR112022004995A 2019-09-18 2020-09-17 Anticorpos biespecíficos contra ceacam5 e cd3 BR112022004995A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902150P 2019-09-18 2019-09-18
EP19198124 2019-09-18
PCT/IB2020/058690 WO2021053587A1 (en) 2019-09-18 2020-09-17 Bispecific antibodies against ceacam5 and cd3

Publications (1)

Publication Number Publication Date
BR112022004995A2 true BR112022004995A2 (pt) 2022-06-21

Family

ID=72615918

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004995A BR112022004995A2 (pt) 2019-09-18 2020-09-17 Anticorpos biespecíficos contra ceacam5 e cd3

Country Status (14)

Country Link
US (1) US20230136228A1 (pt)
EP (1) EP4013512B1 (pt)
JP (1) JP2022548947A (pt)
KR (1) KR20220113353A (pt)
CN (1) CN114786776A (pt)
AU (1) AU2020350205A1 (pt)
BR (1) BR112022004995A2 (pt)
CA (1) CA3150265A1 (pt)
CL (1) CL2022000663A1 (pt)
CO (1) CO2022004685A2 (pt)
IL (1) IL291482A (pt)
MX (1) MX2022003110A (pt)
PE (1) PE20221045A1 (pt)
WO (1) WO2021053587A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023002017A (es) 2020-08-20 2023-04-28 A2 Biotherapeutics Inc Composiciones y métodos para tratar cánceres positivos para ceacam.
CA3188862A1 (en) 2020-08-20 2022-02-24 Carl Alexander Kamb Compositions and methods for treating mesothelin positive cancers
US20240002544A1 (en) 2022-03-07 2024-01-04 Novimmune Sa Cd28 bispecific antibodies for targeted t cell activation
WO2023180489A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen
CN116925232A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 靶向ceacam和cd3的多特异性抗体及其用途
WO2023242351A1 (en) 2022-06-16 2023-12-21 Lamkap Bio Beta Ag Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US20020165360A1 (en) 2000-11-30 2002-11-07 Junghans Richard P. Chimeric effector cell receptors against carcinoembryonic antigen
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
KR101498834B1 (ko) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
HUE026039T2 (en) 2005-07-01 2016-05-30 Squibb & Sons Llc Human monoclonal antibodies programmed for death ligand 1 (PD-L1)
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
KR101287777B1 (ko) 2005-12-21 2013-07-23 암젠 리서치 (뮌헨) 게엠베하 가용성 ｃｅａ에 대한 내성을 가지는 약학적 조성물
IL177158A0 (en) 2006-07-30 2008-01-20 Assaf Klar Method for designing and implementing improved longitudinal flexibility multilayered pipeline
WO2008119566A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
CN101687915B8 (zh) 2007-04-03 2018-08-03 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
HUE040467T2 (hu) 2007-04-03 2019-03-28 Amgen Res Munich Gmbh Keresztfaj-specifikus kötõdomén
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
KR20090010580A (ko) 2007-07-24 2009-01-30 조용식 페트용 토이렛
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
EP4160212B1 (en) 2008-01-15 2024-04-17 The Board of Trustees of the Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
ES2639857T3 (es) 2008-02-11 2017-10-30 Cure Tech Ltd. Anticuerpos monoclonales para el tratamiento del tumor
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
DK2350129T3 (en) 2008-08-25 2015-08-31 Amplimmune Inc PREPARATIONS WITH PD-1 ANTAGONISTS AND PROCEDURES FOR USE THEREOF
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
DK2352763T4 (da) 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
EP3375790A1 (en) 2008-10-01 2018-09-19 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
MX2011003502A (es) 2008-10-01 2011-09-01 Micromet Ag Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies.
TWI686405B (zh) 2008-12-09 2020-03-01 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
WO2011143624A2 (en) 2010-05-14 2011-11-17 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
US9834615B2 (en) 2010-08-16 2017-12-05 Novimmune Sa Methods for the generation of multispecific and multivalent antibodies
CN103403029B (zh) 2011-03-02 2015-11-25 罗切格利卡特公司 抗cea抗体
CN103842383B (zh) 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
US20140242081A1 (en) 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers
EA026924B1 (ru) 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
WO2013055958A1 (en) 2011-10-11 2013-04-18 Genentech, Inc. Improved assembly of bispecific antibodies
JP6435193B2 (ja) 2011-10-19 2018-12-05 ノビミューン エスアー 抗体を精製する方法
CN104271757B (zh) 2012-02-06 2020-06-09 印希彼有限公司 Cd47抗体及其使用方法
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
BR112014028826A8 (pt) 2012-05-15 2021-07-20 Bristol Myers Squibb Co anticorpos monoclonais, uso de anticorpos anti-pd1, anti-pd-l1 e anti-ctla-4 em imunoterapia e tratamento de câncer, bem como kits e processo de seleção de indivíduo para tratamento com anticorpo anti-pd-1
SG11201503285TA (en) 2012-11-20 2015-05-28 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
CN105121467B (zh) 2012-12-03 2019-07-05 诺夫免疫股份有限公司 抗cd47抗体及其使用方法
WO2014131711A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
EP2961771B1 (en) 2013-02-26 2020-01-01 Roche Glycart AG Bispecific t cell activating antigen binding molecules specific to cd3 and cea
CA2920113A1 (en) 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and dinaciclib
ES2728668T3 (es) 2014-01-08 2019-10-28 Univ Leland Stanford Junior Terapia dirigida para el cáncer de pulmón de células pequeñas
US20170015758A1 (en) 2014-01-21 2017-01-19 Medimmune, Llc Compositions And Methods For Modulating And Redirecting Immune Responses
SG11201700207WA (en) 2014-07-11 2017-02-27 Genentech Inc Anti-pd-l1 antibodies and diagnostic uses thereof
WO2016036678A1 (en) 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
EP3261678B8 (en) 2015-01-23 2021-03-17 Helix Biopharma Corp. Antibody-urease conjugates for therapeutic purposes
WO2016156537A1 (en) 2015-03-31 2016-10-06 Novimmune Sa Method for optimizing the assembly and production of hetero-multimeric protein complexes
EP3356410B1 (en) 2015-10-02 2021-10-20 F. Hoffmann-La Roche AG Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
GB2546072B (en) 2016-01-05 2019-07-10 Bja Trading Ltd Attachment assembly and method of using same
US10596257B2 (en) 2016-01-08 2020-03-24 Hoffmann-La Roche Inc. Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
CN109152837A (zh) 2016-04-15 2019-01-04 小利兰·斯坦福大学托管委员会 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
JP2019518742A (ja) 2016-05-09 2019-07-04 セルジーン コーポレーションＣｅｌｇｅｎｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｃｄ４７抗体およびその使用方法
KR20230142658A (ko) 2016-08-03 2023-10-11 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴
WO2018053328A1 (en) 2016-09-16 2018-03-22 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
WO2018199593A1 (ko) 2017-04-24 2018-11-01 재단법인 목암생명과학연구소 Her3 및 cd3에 결합하는 이중특이적 항체
WO2019054559A1 (ko) 2017-09-15 2019-03-21 엘지전자 주식회사 Brir/rir 파라미터화(parameterization)를 적용한 오디오 인코딩 방법 및 파라미터화된 brir/rir 정보를 이용한 오디오 재생 방법 및 장치
CN111699005A (zh) 2018-02-12 2020-09-22 四十七公司 使用抗cd47抗体和抗cd20抗体的抗癌方案
JP7377590B2 (ja) 2018-03-14 2023-11-10 ノビミューン エスアー 抗ｃｄ３イプシロン抗体およびそれを使用する方法

Also Published As

Publication number Publication date
EP4013512A1 (en) 2022-06-22
PE20221045A1 (es) 2022-06-22
CO2022004685A2 (es) 2022-07-08
IL291482A (en) 2022-05-01
JP2022548947A (ja) 2022-11-22
EP4013512B1 (en) 2024-02-14
MX2022003110A (es) 2022-06-27
AU2020350205A1 (en) 2022-05-12
EP4013512C0 (en) 2024-02-14
CA3150265A1 (en) 2021-03-25
US20230136228A1 (en) 2023-05-04
WO2021053587A1 (en) 2021-03-25
CL2022000663A1 (es) 2023-01-06
KR20220113353A (ko) 2022-08-12
CN114786776A (zh) 2022-07-22

Similar Documents

Publication Publication Date Title
BR112022004995A2 (pt) Anticorpos biespecíficos contra ceacam5 e cd3
PH12020551211A1 (en) Antibodies binding to gprc5d
CR20210330A (es) ANTICUERPOS QUE SE UNEN A CD3 (Divisional 2021-0325)
MX2020013122A (es) Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47).
PH12019502640A1 (en) Antibodies specific for flt3 and their uses
MX2019010972A (es) Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
TN2018000325A1 (en) ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALL Y BINDING TO CD3 AND/OR CD123.
MX2022001156A (es) Anticuerpos que se fijan a gprc5d.
PH12020551153A1 (en) Antibodies specific for cd70 and their uses
CL2018001175A1 (es) Anticuerpos anti-il1rap, moleculas de union de antigenos bioespecificos que unen il1rap y cd3 y usos de los mismos.
EA201890390A1 (ru) БИСПЕЦИФИЧЕСКИЕ КОНСТРУКТЫ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ EGFRvIII И CD3
NZ760841A (en) Agonist antibodies that bind human cd137 and uses thereof
CR20220256A (es) Anticuerpos que se unen a hla-a2/mage-a4
PH12019502274A1 (en) Antibodies binding to steap-1
MX2020006119A (es) Anticuerpos de union a hla-a2/wt1.
MX2022015204A (es) Anticuerpos que se unen a cd3.
CR20220637A (es) Anticuerpos que se unen a cd3 y cd19
MX2021000783A (es) Anticuerpos humanizados contra psma.
MX2020008289A (es) Moleculas biespecificas de union al antigeno y metodos de uso.
BR112022008652A2 (pt) Anticorpos biespecíficos hla-a2/wt1 x cd3, uso de um anticorpo biespecífico, método para tratar câncer em um indivíduo, kit e invenção